Back to Search
Start Over
Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
- Source :
-
Investigational new drugs [Invest New Drugs] 2015 Oct; Vol. 33 (5), pp. 1148-50. Date of Electronic Publication: 2015 Sep 04. - Publication Year :
- 2015
-
Abstract
- Alectinib, the second generation anaplastic lymphoma kinase (ALK) inhibitor, has significant potency in patients with ALK rearrangement positive non-small cell lung cancer (NSCLC), and its toxicity is generally well tolerable. We report a patient who developed severe acute interstitial lung disease after alectinib treatment. An 86-year-old woman with stage IV lung adenocarcinoma positive for rearrangement of ALK gene was treated with alectinib. On the 215th day after initiation of alectinib administration, she was admitted to our hospital with the symptom of progressive dyspnea. Computed tomography (CT) revealed diffuse ground glass opacities and consolidations in both lungs, and analysis of bronchoalveolar lavage fluid revealed pronounced lymphocytosis. There was no evidence of infection or other specific causes of her condition, and she was therefore diagnosed with interstitial lung disease induced by alectinib. Her CT findings and respiratory condition improved after steroid pulse therapy. As far as we are aware, this is the first reported case of alectinib-induced severe interstitial lung disease (ILD). We should be aware of the possibility of such a severe adverse event and should therefore carefully monitor patients treated with this drug.
- Subjects :
- Adenocarcinoma of Lung
Adrenal Cortex Hormones therapeutic use
Aged, 80 and over
Anaplastic Lymphoma Kinase
Antineoplastic Agents therapeutic use
Carbazoles therapeutic use
Female
Humans
Lung Diseases, Interstitial drug therapy
Piperidines therapeutic use
Receptor Protein-Tyrosine Kinases genetics
Adenocarcinoma drug therapy
Antineoplastic Agents adverse effects
Carbazoles adverse effects
Carcinoma, Non-Small-Cell Lung drug therapy
Lung Diseases, Interstitial chemically induced
Lung Neoplasms drug therapy
Piperidines adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 1573-0646
- Volume :
- 33
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Investigational new drugs
- Publication Type :
- Academic Journal
- Accession number :
- 26334220
- Full Text :
- https://doi.org/10.1007/s10637-015-0284-9